Drug Trial Radar · NCT00631462
A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis
Last checked: Nov 21, 2026Latest source record: Oct 26, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Jan 2008
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- TargeGenIndustry
- Sponsor type
- Industry
- First posted
- Mar 7, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.
Conditions
- Myelofibrosis
Interventions
TG101348Drug
Orally administered, once a day, for 28 days, up to 6 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety (i.e., adverse events; effects on laboratory parameters, vital signs, and ECGs; dose-limiting toxicities), tolerability, and MTDTime frame: 28 days
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
UCSD Moores Cancer Center
San Diego, California
Stanford Comprehensive Cancer Center
Stanford, California
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Mayo Clinic, Rochester
Rochester, Minnesota
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.